Charity walk raises more than £168,000 for end-of-life care
A charity walk has raised more than £168,000 for end-of-life care.
The Oakhaven Walk took place last month, with 665 participants walking to Oakhaven Hospice in Lymington from Sandbanks, Mudeford, and Barton on Sea.
The event raised £168,700 for the hospice, which provides palliative and end-of-life care and support to families throughout the New Forest, Totton, and Waterside communities.
Jill West, Oakhaven's community and events fundraising manager, said: "Support for this year's Oakhaven Walk has been phenomenal.
14-mile Oakhaven Walk participants before the start in Mudeford (Image: Oakhaven Hospice) "On behalf of everyone at Oakhaven, I would like to say a huge thank you to all the walkers and everyone who supported our fundraising walk.
"You joined together to make every moment matter for your local hospice and have raised a record-breaking amount in sponsorship."
Matt Dukes, managing director at Pennyfarthing Homes, was one of those walking to raise money for Oakhaven Hospice.
He said: "Pennyfarthing Homes is delighted to be able to sponsor such a worthy local cause, providing Oakhaven Hospice with much-needed funds to help run the hugely important Oakhaven Walk.
Oakhaven Walkers on coastal paths near Barton on Sea (Image: Oakhaven Hospice) "As a family business that has built homes here for over 40 years, our connections with the local community run deep in this beautiful part of England, including with the Oakhaven Hospice.
"All of us at Pennyfarthing take immense pride in knowing that we are making a difference to this invaluable charity and the people it supports.
"The Oakhaven Hospice doesn't just provide end-of-life care, it offers crucial support to the whole family, friends and loved ones – helping to ease the pain during one of life's most difficult times."
For more than 30 years, Oakhaven Hospice has provided compassionate end-of-life care to patients and their loved ones, both in the hospice and in patients' homes.
The charity supports a community of more than 150,000 people across the New Forest, Totton, and Waterside.
Demand is growing for Oakhaven's vital services; currently, at any time, around 450 patients plus their families receive support in the hospice and/or in their homes from the Oakhaven teams, free of charge.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
World must ‘start screening for prostate cancer to stop men being left behind'
Every country should have a strategy for tackling prostate cancer with dedicated screening programs for men over 50, a leading health charity has said. Global Action on Men's Health, the leading international charity for men's health, is calling for prostate cancer – now the third most common cancer worldwide – to be dramatically elevated on the health agenda. On Monday it will launch a campaign to encourage all countries with adequate resources, including the UK, to launch national screening for the disease in a bid to cut unnecessary deaths. It will also call for the World Health Organization (WHO) to introduce a Global Prostate Cancer Initiative which 'covers every stage of the prostate cancer pathway from prevention to palliative care'. Prostate cancer is now the most frequently diagnosed cancer in men in 112 countries and the leading cause of cancer death among men in 48 countries. In England, it is now the most common cancer, killing some 12,000 men every year, according to Prostate Cancer UK. Writing in today's Telegraph, Peter Baker, the director of Global Action on Men's Health, said that men were being short-changed when it comes to healthcare. 'Men's health has been neglected for far too long with devastating consequences,' he writes. 'Globally, men's life expectancy lags five years behind women's. Men are significantly more likely to develop and die from cancer, heart disease, diabetes and tuberculosis. They are also at much greater risk of dying from suicide or an accident on the roads or at work.' Mr Baker calls for reform across health care systems – ensuring men have better access to GPs, for instance – and believes that a focus on prostate cancer is a good place to start. Rapid advances in screening technologies now mean that developed nations should soon be able to launch screening programs that will cut death rates by a third or more and reduce the dramatic social inequalities associated with the disease. Men with a family history of prostate cancer run a significantly higher genetic risk of developing prostate cancer, as do black men. Men from lower socioeconomic backgrounds are also much harder hit, due to a combination of poor health literacy and access to healthcare. The European Commission recently recommended introducing national prostate cancer screening across all 27 member states of the European Union, and already countries including Sweden and Norway have either launched or are on the brink of launching national screening programs. While blood tests for prostate cancer, known as prostate-specific antigen tests (PSA), have been available for many years, they throw up a large number of false positives. This in turn led to many unnecessary prostate removals and biopsies being performed, meaning the risks outweighed the benefits of running national screening programmes. But now, with the advent of more specific blood tests and high resolution MRI scans, which allow for much more accurate biopsies, the balance has changed, with several high quality studies showing the benefit of screening. The largest of these studies was the European Randomised Study of Screening for Prostate Cancer (ERSPC), which included over 182,000 men and showed a 20 per cent reduction in prostate cancer mortality among those screened. Another study in Gothenburg, Sweden, found that after 18 years of follow-up, men in the screening group were 35 per cent less likely to die from prostate cancer than men who were not screened. Men who started screening at age 55-59 were 53 per cent less likely to die. Professor Jonas Hugosson, a urologist at University of Gothenburg in Sweden who led the Swedish study, said he expected national screening for prostate cancer to be rolled out across most western European nations in the next few years. In Sweden a move to nationwide screening was already progressing and in Norway he expected a national screening program to be announced shortly, he said. However, just as with the roll out of breast cancer screening more than three decades ago, it would take most countries many years to gear up. 'In my view, we have quite a new situation today, and I think it's time for the health authorities to take a new standpoint,' he said. 'I'm quite sure about that and we will see screening come all over Europe during the coming years, but it takes 10 years to build up, at least.' The NHS in England does not have a dedicated men's health strategy but one has been promised by the end of the year by the new Health Secretary, Wes Streeting. Although the new strategy is unlikely to include the imminent launch of a national screening program for prostate cancer – the UK currently does not have the MRI machines and trained staff needed to launch one – it may include screening for high risk groups. These include black men, who have double the normal risk, and men with a family history of prostate and related cancers – including breast and ovarian cancer on the female side. In October last year, six-time Olympic cycling champion Sir Chris Hoy, 49, revealed that he had terminal prostate cancer. Both his father and grandfather had the disease but his was not caught by early testing, sparking an outcry. 'The rapid rise in prostate cancer cases is not just alarming, it is also unnecessary and therefore unacceptable,' said Global Action on Men's Health. 'Prostate cancer is currently inadequately addressed in global and national cancer policies'. In addition to national testing where possible, the charity is calling for the WHO to support a new Global Prostate Cancer Initiative covering 10 areas. These include governments being urged to introduce national cancer plans which specifically address prostate cancer with clear performance indicators, education programmes to raise awareness and tackle stigma, and investments in research, infrastructure, workforce development and treatments for prostate cancer. The WHO does not currently have a programme that focuses specifically on prostate cancer but 'integrates' it to its wider program for tackling cancer more generally. Cervical cancer, in contrast, has a dedicated programme dedicated to its global eradication but that is because the HPV vaccine makes it possible to wipe out the disease completely. Dr André Ilbawi, technical lead for cancer control at the WHO, welcomed the prostate campaign launched by Global Action on Men's Health, and said the disease was moving up the WHO's agenda. The organisation had just five countries involved in its cancer programme in 2015 to but has 100 today. 'We see prostate cancer as a priority and, in 2023, elevated it in our guidance because it can be treated,' said Dr IIbawi. 'If treatment is available, survival is extremely high. And if treatments are not available, those men will die. 'We agree that prostate cancer should be seen in the cancer agenda as high impact, cost-effective and meeting community needs'. Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Medscape
an hour ago
- Medscape
Add-On Niraparib May Slow mHSPC
Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) genetic alterations, according to findings from the AMPLITUDE trial. An interim analysis also demonstrated an early trend toward improved overall survival in patients who received niraparib. These findings support adding niraparib to abiraterone acetate plus prednisone 'as a new treatment option' in patients with HRR alterations, said Study Chief Gerhardt Attard, MD, PhD, chair of medical oncology, University College London Cancer Institute, London, England, speaking at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. The findings also highlight that 'it's going to be incredibly important that patients who get diagnosed with hormone-sensitive prostate cancer are tested to see if they have these mutations, so they can be offered the right therapy at the right time,' Outside Expert Bradley McGregor, MD, with Dana-Farber Cancer Institute in Boston, said during a press briefing. Ultimately, 'you don't know if you don't test,' McGregor added. About one quarter of patients with metastatic castration-sensitive prostate cancer have alterations in HRR genes, about half of which are BRCA mutations. These patients typically experience faster disease progression and worse outcomes. An androgen receptor pathway inhibitor, such as abiraterone, alongside androgen deprivation therapy with or without docetaxel, is standard therapy for these patients, but 'there is still a need for treatments that are tailored to patients whose tumors harbor HRR alterations,' Attard said in a press release. Adding niraparib to this standard regimen could help improve survival in these patients. In 2023, the FDA approved niraparib and abiraterone acetate to treat BRCA -mutated metastatic castration-resistant prostate cancer, after findings from the MAGNITUDE study demonstrated improved progression-free survival (PFS). The phase 3 AMPLITUDE trial set out to evaluate whether this combination would yield similar survival benefits in metastatic castration-sensitive prostate cancer with HRR mutations. In the study, 696 patients (median age, 68 years) with metastatic castration-sensitive prostate cancer and one or more HRR gene alterations were randomly allocated (1:1) to niraparib with abiraterone acetate plus prednisone or placebo with abiraterone acetate plus prednisone. Exclusion criteria included any prior PARP inhibitor therapy or androgen receptor pathway inhibitor other than abiraterone. Eligible patients could have received at most 6 months of androgen deprivation therapy, ≤ 6 cycles of docetaxel, ≤ 45 days of abiraterone acetate plus prednisone and palliative radiation. Baseline characteristics were well balanced between the groups. Just over half the patients in each group had BRCA1 or BRCA2 alterations. The majority had an electrocorticogram performance status of 0, but high-risk features with a predominance for synchronous metastatic disease and metastatic high volume. About 16% had received prior docetaxel, in keeping with real world data, Attard noted. At a median follow-up of 30.8 months, niraparib plus standard therapy led to a significant 37% reduction in the risk for radiographic progression or death. The median radiographic PFS (rPFS) was not reached in the niraparib group vs 29.5 months in the placebo group (hazard ratio [HR], 0.63; P = .0001). Patients with BRCA alterations, in particular, showed the greatest benefit, with niraparib reducing the risk for radiographic progression or death by 48% compared to placebo (median rPFS not reached vs 26 months; HR, 0.52; P < .0001). On the key secondary endpoint of time to symptomatic progression, adding niraparib led to a 'statistically and clinically' significant benefit — a 50% lower in the risk for symptomatic progression in the full population (HR, 0.50), and a 56% lower risk in BRCA -mutant group (HR, 0.44). The first interim analysis also showed an early trend toward improved overall survival favoring the niraparib combination, with a reduction in the risk for death of 21% in the HRR-mutant population (HR, 0.79; P = .10) and 25% (HR, 0.75; P = .15) in the BRCA -mutant population. Grade 3/4 adverse events were more common with the niraparib combination group compared to the placebo group (75% vs 59%), with anemia and hypertension being the most common. However, treatment discontinuations due to adverse remained low (15% with niraparib vs 10% with placebo). Attard noted, however, that half the target number of patients required for the final analysis died. Still, 'in my view, there's a clear trend for favoring survival in the patients randomized to niraparib,' he told attendees. 'Exciting News' for Patients The AMPLITUDE results are 'really exciting news for our patients,' McGregor said. Considering the poor prognosis of patients with metastatic castration-sensitive prostate cancer, 'it is reasonable to prioritize early access to PARP inhibitors for these men, at least for the ones with BRCA mutations,' added ASCO discussant Joaquin Mateo, MD, PhD, with Vall d'Hebron Institute of Oncology, Barcelona, Spain. However, Mateo explained, 'I think that for patients with mutations in the other genes, I will be more prudent, and I'll be on the lookout for the overall survival data to mature.' The other key conclusion, Mateo said, is that genomic profiling 'should be moved earlier into the patient course, and I am confident that embedding genomic profiling into the diagnostic evaluations of metastatic prostate cancer is also going to result in better quality of testing, more efficacious testing, and also a more equitable framework of access to testing for patients.'
Yahoo
2 hours ago
- Yahoo
Healthcare firm Totally collapses but divisions sold
Former NHS 111 urgent care provider Totally has collapsed into administration, but said a deal to sell its main divisions will see the 'uninterrupted provision' of all its services. The Derby-based healthcare firm – which lost the NHS 111 support contract in February this year – has appointed Ernst & Young partners Tim Vance and Sam Woodward as joint administrators after failing to secure bids or strategic investors for the entire firm. It said that following the appointment, the sale of its selective care and corporate wellbeing subsidiaries, as well as the urgent care division, was completed to rival PHL Group. 'This transaction sees the continued and uninterrupted provision of all services previously delivered by the group,' Totally said. Totally employed more than 1,400 employees, according to its 2023-2024 annual report. The group added: 'PHL Group will make separate announcements shortly, including communication with the customers, suppliers and employees of the elective care and urgent care divisions, and the corporate wellbeing business, which are all continuing to provide all services as normal following the transaction.' The company's failure comes after a difficult past year, with the firm losing the NHS 111 contract worth £13 million and then revealing last month it was facing a potential medical negligence claim related to an incident in January 2018. At the time, it warned the size of the liability for the claim could be more than the £10 million claim limit on its insurance policy. It launched a strategic review to look at options, including the sale of subsidiaries 'receiving strategic investment or undertaking some other form of comparable corporate action'. Shares in the firm plummeted at the time. On June 6, it announced its intention to appoint administrators after the review had failed to see any 'solvent' offers for parent firm Totally and suspended its shares from trading on London's junior Aim market. PHL – the buyer of its trading divisions – was launched in 2009 and runs services in the UK and overseas, including integrated urgent care, urgent treatment centres, surgical insourcing, custody healthcare, ADHD services and general practice. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
